Advice

Following a full submission

1 mg estradiol / 2 mg drospirenone (Angeliq) is not recommended for use within NHS Scotland for prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or have contra-indications to, other medicinal products approved for the prevention of osteoporosis.

It maintains bone mineral density, relative to placebo, in post-menopausal women. However, no evidence of cost-effectiveness has been presented.

Medicine details

Medicine name:
1 mg estradiol/2 mg drospirenone (Angeliq®)
SMC ID:
227/05
Indication:
Prevention of osteoporosis
Date advice published:
09 January 2006
Archive advice

test